Review
Selective Serotonin Reuptake Inhibitors and Increased Bleeding Risk: Are We Missing Something?

https://doi.org/10.1016/j.amjmed.2005.03.044Get rights and content

Abstract

Purpose

Selective serotonin reuptake inhibitors (SSRIs) are first line agents to treat clinical depression. Although these medications exhibit a favorable safety profile, there are multiple case reports, registries, and uncontrolled studies suggesting that use of SSRIs might be associated in the increased risk of bleeding events. There is also emerging evidence that these side effects of SSRIs are due to blockade of serotonin reuptake in platelets and subsequent platelet dysfunction.

Methods

The analysis of evidence linking SSRIs with bleeding episodes to define the prevalence, specific clinical characteristics, and estimated risk when SSRIs are used in combination with antiplatelet agents or/and anticoagulants.

Results

There are over 120 MEDLINE-cited peer-reviewed research papers and more than 50 000 Web pages devoted to SSRI-related bleeding events.

Conclusion

Independently of the brand, use of SSRIs is indeed associated with increased bleeding risk. Although such complications are rare, their frequency is growing, and physicians should be aware of SSRI-induced hemorrhages, especially in patients with hereditary platelet defects, and those treated with antiplatelet agents. Prospective studies are urgently needed to determine whether SSRIs will yield additional bleeding risks when used long term concomitantly with aspirin or clopidogrel.

References (53)

  • J. Higham et al.

    Recent trends in admissions and mortality due to peptic ulcer in Englandincreasing frequency of haemorrhage among older subjects

    Gut

    (2002)
  • P.J. Neafsey

    Adverse self-medication practices among individuals taking SSRI ntidepressants

    Home Healthc Nurse

    (2004)
  • S.O. Dalton et al.

    Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleedinga population-based cohort study

    Arch Intern Med.

    (2003)
  • V.L. Serebruany et al.

    Effects of valsartan and valeryl 4-hydroxy valsartan on human plateletsa possible additional mechanism for clinical benefits

    J Cardiovasc Pharmacol.

    (2004)
  • P.A. Kubler et al.

    Concordance between clopidogrel use and prescribing guidelines

    Intern Med J

    (2004)
  • M. Moonis et al.

    Antiplatelet treatment for secondary prevention of acute ischemic stroke and transient ischemic attacksmechanisms, choices and possible emerging patterns of use

    Expert Rev Cardiovasc Ther.

    (2003)
  • B.H. Stricker et al.

    Registration of suspected adverse effects by the Bureau Adverse Effects Drugs; research activities in 1993

    Ned Tijdschr Geneeskd.

    (1994)
  • W.E. Meijer et al.

    Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants

    Arch Intern Med.

    (2004)
  • R. Ramasubbu

    Cerebrovascular effects of selective serotonin reuptake inhibitorsa systematic review

    J Clin Psychiatry

    (2004)
  • J. Butler et al.

    The platelet serotonergic system in depression and following sertraline treatment

    Int J Clin Psychopharmacol.

    (1988)
  • J.H. Markovitz et al.

    Platelet activation in depression and effects of sertraline treatmentan open-label study

    Am J Psychiatry

    (2000)
  • D.L. Musselman et al.

    Platelet reactivity in depressed patients treated with paroxetinepreliminary findings

    Arch Gen Psychiatry

    (2000)
  • J.C. Alvarez et al.

    Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depressioneffects of clomipramine and fluoxetine

    Clin Pharmacol Ther.

    (1999)
  • N. Hergovich et al.

    Paroxetine decreases platelet serotonin storage and platelet function in human beings

    Clin Pharmacol Ther.

    (2000)
  • V.L. Serebruany et al.

    Platelet inhibition by sertraline and N-desmethylsertralinea possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors

    Pharmacol Res.

    (2001)
  • V.B. Pai et al.

    Bruising associated with the use of fluoxetine

    Ann Pharmacother.

    (1996)
  • Cited by (0)

    View full text